Keytruda is about to be approved for the fifth indications in China: second-line treatment for esophageal cancer.

On June 16, The fifth indication application for Paboli-Zhusmal anti-injection injection submitted by Mersadong in China was changed to "in approval" and is expected to be formally approved in the near future.
it is understood that Keytruda's approved indicationisis is a second-line treatment for esophageal cancer.
Paboli-Zhu-Sing was first approved in China on July 20, 2018, with one-year sales of 2 billion yuan.
at present, Paboli Zuma has been approved in China 4 indications, in addition to the soon-to-be-approved esophageal cancer indications, there is an indication disorder is still in the review and approval stage.
it is worth noting that the adaptation of Henri PD-1 Carrelli Zhu singular second-line treatment for esophageal scale cancer is also expected to be approved in the near future.
esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of death from cancer. The 5-year relative survival rate of patients with
metastatic esophageal cancer was generally less than 8%. The two most common types of esophageal cancer
are squamous cell cancer and adenocarcinoma, accounting for 90% and 10% of all esophageal cancers, respectively.
about 572,000 new confirmed cases and about 500,000 deaths from esophageal cancer each year.
most patients are diagnosed with advanced stages, affecting their daily lives, including diet.
has the highest incidence of esophageal cancer in Asia, with more than 444,000 confirmed cases per year, accounting for about 80 per cent of the global cases of esophageal cancer.
The keynote-181 Asian subgroup analysis data on the late/metastatic cell cancer of Pabolyzumab-contrast chemotherapy, presented at cSCO2019 conference, showed that Paboli zumas showed OS benefits in Asian patients compared to chemotherapy and had a more favorable safety spectrum (see: Keytruda second-line treatment of Asian esophageal cancer).
pharmaceutical Rubik's Cube database PharmaGo shows that, at present, Mersadon has registered as many as 20 Phase III clinical trials in China for Paboli Zuma, which involveen endometrial cancer, hepatocellular carcinoma, biliary cancer and urinary skin cancer.
.